Evidence map›Paper›PMID 24037024›Full record

ArticleBone marrow transplantation2014

Higher therapeutic CsA levels early post transplantation reduce risk of acute GVHD and improves survival.

J R Rogosheske, A D Fargen, T E DeFor, E Warlick, M Arora, B R Blazar, D J Weisdorf, C G Brunstein

Open access · greenAbstract read
In one paragraph

Article in Bone marrow transplantation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 48 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Higher Dose of Mycophenolate Mofetil Reduces Acute Graft-versus-Host Disease in Reduced-Intensity Conditioning Double Umbilical Cord Blood Transplantation.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2015
    Trial
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Optimal Practices in Unrelated Donor Cord Blood Transplantation for Hematologic Malignancies.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2017
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

J R RogosheskeUniversity of Minnesota Blood and Marrow Transplant Program, Minneapolis, MN, USA.
A D FargenUniversity of Minnesota Blood and Marrow Transplant Program, Minneapolis, MN, USA.
T E DeForUniversity of Minnesota Blood and Marrow Transplant Program, Minneapolis, MN, USA.
E WarlickUniversity of Minnesota Blood and Marrow Transplant Program, Minneapolis, MN, USA.
M AroraUniversity of Minnesota Blood and Marrow Transplant Program, Minneapolis, MN, USA.
B R BlazarUniversity of Minnesota Blood and Marrow Transplant Program, Minneapolis, MN, USA.
D J WeisdorfUniversity of Minnesota Blood and Marrow Transplant Program, Minneapolis, MN, USA.
C G BrunsteinUniversity of Minnesota Blood and Marrow Transplant Program, Minneapolis, MN, USA.
University of Minnesota · USNational Marrow Donor Program · US

Funding

Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI HEATHER Hammond NELSON · 1998 to 2026
$100.4M
Trial Design and Biostatistical Support CoreP01CA065493 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI J SUNIL RAO · 1995 to 2026
$48.2M
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR000114 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R · 2012 to 2015
$35.0M
IN VIVO PREVENTION OF MURINE GVHDR01AI034495 · NIAID · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BLAZAR, BRUCE R · 1993 to 2016
$6.2M
NCATS NIH HHS UL1 TR000114NCI NIH HHS P01 CA065493NCI NIH HHS P01 CA65493NCI NIH HHS P30 CA077598NIAID NIH HHS R01 AI034495
6 · The paper itself

Abstract

We studied whether early CsA trough levels were associated with the risk of acute GVHD in 337 patients after either sibling PBSC or double umbilical cord blood transplantation. All patients, regardless of donor type, started CsA at a dose of 5 mg/kg i.v. divided twice daily, targeting trough concentrations 200-400 ng/mL. The CsA level was studied by a weighted average method calculated by giving 70% of the weight to the level that was measured just before the onset of the event or day +30. We found that higher weighted average CsA trough levels early post transplantation contributed to lower risk of acute GVHD, and lower non-relapse and overall mortality. Thus, our data support close monitoring with active adjustments of CsA dosing to maintain therapeutic CsA levels in the first weeks of allo-HCT. In patients who are near or even modestly above the CsA target trough level, in the absence of CsA-related toxicity, dose reduction should be cautious to avoid subtherapeutic drug levels resulting in higher risk of acute GVHD.

Indexed as

Hematopoietic Stem Cell TransplantationAdolescentAdultAllelesCalcineurin InhibitorsCord Blood Stem Cell TransplantationCyclosporineFemaleGraft vs Host DiseaseHematologic NeoplasmsHumansImmunosuppressive AgentsMaleMiddle AgedMultivariate AnalysisRecurrenceCalcineurin InhibitorsCyclosporineImmunosuppressive Agents

Identifiers

PMID24037024
PMCPMC3947241
OpenAlexW2034017748

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.